Menu
About us
Rosetta is a specialist UK-based life science venture capital firm that invests globally to build leading healthcare companies and breakthrough technologies that can deliver benefits to human lives. We invest through direct secondary transactions to provide flexible liquidity solutions to investors or corporations
Our investment strategy is focused on direct secondary transactions.
Rosetta has made 50+ venture investments through direct secondary transactions over 20+ years and has vast experience of completing transactions in an efficient manner.
As a secondary investor, we provide flexible liquidity solutions for other investors or corporations that wish to divest some or all of their investment assets or to access additional capital and resource to optimise investment outcomes.
We bring new capital to participate in follow-on financings and help support the company through value-adding inflection points.
We are an experienced team that engages strategically with our portfolio company Boards, management teams and co-investors to help secure successful corporate partnerships, IPOs and trade sales.
We have an exceptional track record over 21 years:
0
founded in
Global investment horizon
with a track record of executing transactions across North America and Europe
funds
raised and deployed across the life sciences and medical device sectors
$
million
in historical commitments
0
+
IPO and M&A exits, mostly on NASDAQ and European exchanges
Find out more
Case studies
We have an experienced investment team that has a long history of completing secondary transactions with European and North American healthcare investors to acquire equity positions in portfolio companies.
